Inhibitory effect of selective cyclooxygenase-2 inhibitor etoricoxib on human Organic anion transporter 3 (hOAT3)

Drug Metabolism Letters

Volumn 5, Issue 2, 2011, Pages 137-140

  Honjo, Hiroaki ^a   Uwai, Yuichi ^a   Iwamoto, Kikuo ^a  

^a AICHI GAKUIN UNIVERSITY   (Japan)

Author keywords

Drug interaction; Etoricoxib; HOAT3; Methotrexate; Transport

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; ESTRONE SULFATE; ETORICOXIB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; ORGANIC ANION TRANSPORTER 3; ORGANIC ANION TRANSPORTER; PYRIDINE DERIVATIVE; SULFONE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG ELIMINATION; DRUG MECHANISM; DRUG UPTAKE; NONHUMAN; OOCYTE; PRIORITY JOURNAL; XENOPUS LAEVIS; ANIMAL; DOSE RESPONSE; DRUG ANTAGONISM; HUMAN; METABOLISM;

XENOPUS LAEVIS;

ANIMALS; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; METHOTREXATE; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; PYRIDINES; SULFONES; XENOPUS LAEVIS;

EID: 79954523545     PISSN: 18723128     EISSN: None     Source Type: Journal    
DOI: 10.2174/187231211795305285     Document Type: Article

References (19)

1. Bannwarth, B.; Péhourcq, F.; Schaeverbeke, T.; Dehais, J. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin. Pharmacokinet., 1996, 30, 194-210.
2. Thyss, A.; Milano, G.; Kubar, J.; Namer, M.; Schneider, M. Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet, 1986, 327, 256-258.
3. Liegler, D.G.; Henderson, E.S.; Hahn, M.A.; Oliverio, V.T. The effect of organic acids on renal clearance of methotrexate in man. Clin. Pharmacol. Ther., 1969, 10, 849-857.
4. Motohashi, H.; Sakurai, Y.; Saito, H.; Masuda, S.; Urakami, Y.; Goto, M.; Fukatsu, A.; Ogawa, O.; Inui, K. Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J. Am. Soc. Nephrol., 2002, 13, 866-874.
5. Takeda, M.; Khamdang, S.; Narikawa, S.; Kimura, H.; Hosoyamada, M.; Cha, S.H.; Sekine, T.; Endou, H. Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J. Pharmacol. Exp. Ther., 2002, 302, 666-671.
6. Uwai, Y.; Taniguchi, R.; Motohashi, H.; Saito, H.; Okuda, M.; Inui, K. Methotrexate-loxoprofen interaction: involvement of human organic anion transporters hOAT1 and hOAT3. Drug Metab. Pharmacokinet., 2004, 19, 369-374.
7. Nozaki, Y.; Kusuhara, H.; Kondo, T.; Iwaki, M.; Shiroyanagi, Y.; Nakayama, H.; Horita, S.; Nakazawa, H.; Okano, T.; Sugiyama, Y. Species difference in the inhibitory effect of nonsteroidal antiinflammatory drugs on the uptake of methotrexate by human kidney slices. J. Pharmacol. Exp. Ther., 2007, 322, 1162-1170.
8. Maeda, A.; Tsuruoka, S.; Kanai, Y.; Endou, H.; Saito, K.; Miyamoto, E.; Fujimura, A. Evaluation of the interaction between nonsteroidal anti-inflammatory drugs and methotrexate using human organic anion transporter 3-transfected cells. Eur. J. Pharmacol., 2008, 596, 166-172.
9. Shi, S.; Klotz, U. Clinical use and pharmacological properties of selective COX-2 inhibitors. Eur. J. Clin. Pharmacol., 2008, 64, 233-252.
10. Karim, A.; Tolbert, D.S.; Hunt, T.L.; Hubbard, R.C.; Harper, K.M.; Geis, G.S. Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis. J. Rheumatol., 1999, 26, 2539-2543.
11. Hartmann, S.N.; Rordorf, C.M.; Milosavljev, S.; Branson, J.M.; Chales, G.H.; Juvin, R.R.; Lafforgue, P.; Le Parc, J.M.; Tavernier, C.G.; Meyer, O.C. Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. Ann. Pharmacother., 2004, 38, 1582-1587.
12. Schwartz, J.I.; Agrawal N.G.; Wong, P.H.; Miller, J.; Bachmann, K.; Marbury, T.; Hoelscher, D.; Cavanaugh, P.F.Jr.; Gottesdiener, K. Examination of the effect of increasing doses of etoricoxib on oral methotrexate pharmacokinetics in patients with rheumatoid arthritis. J. Clin. Pharmacol., 2009, 49, 1202-1209.
13. Maeda, A.; Tsuruoka, S.; Ushijima, K.; Kanai, Y.; Endou, H.; Saito, K.; Miyamoto, E.; Fujimura, A. Drug interaction between celecoxib and methotrexate in organic anion transporter 3-transfected renal cells and in rats in vivo. Eur. J. Pharmacol., 2010, 640, 168-171.
14. Uwai, Y.; Honjo, H.; Iwamoto, K. Inhibitory effect of selective cyclooxygenase-2 inhibitor lumiracoxib on human organic anion transporters hOAT1 and hOAT3. Drug Metab. Pharmacokinet., 2010, 25, 450-455.
15. Uwai, Y.; Iwamoto, K. Transport of aminopterin by human organic anion transporters hOAT1 and hOAT3: comparison with methotrexate. Drug Metab. Pharmacokinet., 2010, 25, 163-169.
16. Takeda, M.; Hosoyamada, M.; Cha, S.H.; Sekine, T.; Endou, H. Hydrogen peroxide downregulates human organic anion transporters in the basolateral membrane of the proximal tubule. Life Sci., 2000, 68, 679-687.
17. Brouwers, J.; de Smet, P. Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs. Clin. Pharmacokinet., 1994, 27, 462-485.
18. Davies, N.M.; McLachlan, A.J.; Day, R.O.; Williams, K.M. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin. Pharmacokinet., 2000, 38, 225-242.
19. Takemoto, J.K.; Reynolds J.K.; Remsberg C.M.; Vega-Villa K.R.; Davies N.M. Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib. Clin. Pharmacokinet., 2008, 47, 703-720.